Skip to main content
SpringerLink
Log in

Homocysteine and cognition in first-episode psychosis patients

  • Original Paper
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

In the last years, there has been growing evidence linking elevated homocysteine levels with cognitive dysfunction in several neurological and neuropsychiatric diseases. The aim of the present study was to investigate the potential relationship between elevated homocysteine levels and cognitive deficits in first-episode psychosis patients. Plasma levels and cognitive performance of 139 patients and 99 healthy volunteers were compared. Patients were classified as elevated homocysteine (>90 percentile for controls) and normal and compared on 22 cognitive outcome measures grouped into cognitive domains known to be impaired in schizophrenia. Patients had a statistically significant increase in plasmatic homocysteine levels. In addition, they presented with significantly increased cognitive deficits. However, no relationship between homocysteine levels and cognitive impairment was detected. These results suggest the need for further studies to clarify the role of homocysteine in the etiology and prognosis of psychosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Andreasen NC (1983) Scale for the assessment of negative symptoms (sans). University of Iowa, Iowa City

    Google Scholar 

  2. Andreasen NC (1984) Scale for the assessment of positive symptoms (saps). University of Iowa, Iowa City

    Google Scholar 

  3. Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I (2001) The “reading the mind in the eyes” test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry 42:241–251

    Article  PubMed  CAS  Google Scholar 

  4. Brown AS, Bottiglieri T, Schaefer CA, Quesenberry CP Jr, Liu L, Bresnahan M, Susser ES (2007) Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry 64:31–39

    Article  PubMed  CAS  Google Scholar 

  5. Carew TG, Lamar M, Cloud BS, Grossman M, Libon DJ (1997) Impairment in category fluency in ischemic vascular dementia. Neuropsychology 11:400–412

    Article  PubMed  CAS  Google Scholar 

  6. Cegalis JBJ (1991) Vigil: Software for the assessment of attention. Forthought Nashua, NH, In

    Google Scholar 

  7. Cortese C, Motti C (2001) Mthfr gene polymorphism, homocysteine and cardiovascular disease. Public Health Nutr 4:493–497

    Article  PubMed  CAS  Google Scholar 

  8. Crespo-Facorro B, Rodriguez-Sanchez JM, Perez-Iglesias R, Mata I, Ayesa R, Ramirez-Bonilla M, Martinez-Garcia O, Vazquez-Barquero JL (2009) Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J Clin Psychiatry 70:717–729

    Article  PubMed  CAS  Google Scholar 

  9. Dias VV, Brissos S, Cardoso C, Andreazza AC, Kapczinski F (2009) Serum homocysteine levels and cognitive functioning in euthymic bipolar patients. J Affect Disord 113:285–290

    Article  PubMed  CAS  Google Scholar 

  10. Dittmann S, Seemuller F, Grunze HC, Schwarz MJ, Zach J, Fast K, Born C, Dargel S, Engel RR, Bernhard B, Moller HJ, Riedel M, Severus WE (2008) The impact of homocysteine levels on cognition in euthymic bipolar patients: a cross-sectional study. J Clin Psychiatry 69:899–906

    Article  PubMed  Google Scholar 

  11. Elias MF, Sullivan LM, D’Agostino RB, Elias PK, Jacques PF, Selhub J, Seshadri S, Au R, Beiser A, Wolf PA (2005) Homocysteine and cognitive performance in the Framingham offspring study: age is important. Am J Epidemiol 162:644–653

    Article  PubMed  Google Scholar 

  12. Evans JJ, Chua SE, McKenna PJ, Wilson BA (1997) Assessment of the dysexecutive syndrome in schizophrenia. Psychol Med 27:635–646

    Article  PubMed  CAS  Google Scholar 

  13. Galderisi S, Davidson M, Kahn RS, Mucci A, Boter H, Gheorghe MD, Rybakowski JK, Libiger J, Dollfus S, Lopez-Ibor JJ, Peuskens J, Hranov LG, Fleischhacker WW (2009) Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study. Schizophr Res 115:104–114

    Article  PubMed  Google Scholar 

  14. Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, Evins AE, Henderson DC, Baer L, Coyle J (2004) Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 161:1705–1708

    Article  PubMed  Google Scholar 

  15. Golden CJ (1975) A group version of the Stroop Color and Word Test. J Pers Assess 39:386–388

    Article  PubMed  CAS  Google Scholar 

  16. Gonzalez-Blanch C, Crespo-Facorro B, Alvarez-Jimenez M, Rodriguez-Sanchez JM, Pelayo-Teran JM, Perez-Iglesias R, Vazquez-Barquero JL (2007) Cognitive dimensions in first-episode schizophrenia spectrum disorders. J Psychiatr Res 41:968–977

    Article  PubMed  Google Scholar 

  17. Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321–330

    PubMed  CAS  Google Scholar 

  18. Harvey PD (2009) When does cognitive decline occur in the period prior to the first episode of schizophrenia? Psychiatry (Edgmont) 6:12–14

    Google Scholar 

  19. Johnson JL, Ratner PA, Malchy LA, Okoli CT, Procyshyn RM, Bottorff JL, Groening M, Schultz A, Osborne M (2010) Gender-specific profiles of tobacco use among non-institutionalized people with serious mental illness. BMC Psychiatry 10:101

    Article  PubMed  Google Scholar 

  20. Kale A, Naphade N, Sapkale S, Kamaraju M, Pillai A, Joshi S, Mahadik S (2010) Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: Implications for altered one-carbon metabolism. Psychiatr Res 175:47–53

    Article  CAS  Google Scholar 

  21. Levine J, Agam G, Sela BA, Garver DL, Torrey EF, Belmaker RH (2005) Csf homocysteine is not elevated in schizophrenia. J Neural Transm 112:297–302

    Article  PubMed  CAS  Google Scholar 

  22. Levine J, Stahl Z, Sela BA, Gavendo S, Ruderman V, Belmaker RH (2002) Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry 159:1790–1792

    Article  PubMed  Google Scholar 

  23. Levine J, Stahl Z, Sela BA, Ruderman V, Shumaico O, Babushkin I, Osher Y, Bersudsky Y, Belmaker RH (2006) Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry 60:265–269

    Article  PubMed  CAS  Google Scholar 

  24. Lezak M (1995) Neuropsychological assessment. Oxford University Press, NY

    Google Scholar 

  25. Ma YY, Shek CC, Wong MC, Yip KC, Ng RM, Nguyen DG, Poon TK (2009) Homocysteine level in schizophrenia patients. Aust N Z J Psychiatry 43:760–765

    Article  PubMed  Google Scholar 

  26. Martin-Fernandez JJ, Carles-Dies R, Canizares F, Parra S, Aviles F, Villegas I, Morsi-Hassan O, Fernandez-Barreiro A, Herrero MT (2010) homocysteine and cognitive impairment in Parkinson’s disease. Rev Neurol 50:145–151

    PubMed  Google Scholar 

  27. Muntjewerff JW, Hoogendoorn ML, Kahn RS, Sinke RJ, Den Heijer M, Kluijtmans LA, Blom HJ (2005) Hyperhomocysteinemia, methylenetetrahydrofolate reductase 677tt genotype, and the risk for schizophrenia: a Dutch population based case-control study. Am J Med Genet B Neuropsychiatr Genet 135B:69–72

    Article  PubMed  Google Scholar 

  28. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK (2004) Identification of separable cognitive factors in schizophrenia. Schizophr Res 72:29–39

    Article  PubMed  Google Scholar 

  29. O’Donnell C, Stephens T (2005) The significance of homocysteine levels in schizophrenia. Am J Psychiatry 162:1387–1388 author reply 1388–1389

    Article  PubMed  Google Scholar 

  30. Obeid R, McCaddon A, Herrmann W (2007) The role of hyperhomocysteinemia and b-vitamin deficiency in neurological and psychiatric diseases. Clin Chem Lab Med 45:1590–1606

    PubMed  CAS  Google Scholar 

  31. Osterrieth PA (1944) Contribution a l’étude de la perception et de la memoire (the test of copying a complex figure: a contribution to the study of perception and memory). Archive de Psychologie 30:286–350

    Google Scholar 

  32. Oulhaj A, Refsum H, Beaumont H, Williams J, King E, Jacoby R, Smith AD (2010) Homocysteine as a predictor of cognitive decline in Alzheimer’s disease. Int J Geriatr Psychiatry 25:82–90

    PubMed  Google Scholar 

  33. Pelayo-Teran JM, Perez-Iglesias R, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Pardo-Garcia G, Rodriguez-Sanchez J, Roiz-Santianez R, Tordesillas-Gutierrez D, Mata I, Vazquez-Barquero JL, Crespo-Facorro B (2008) Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in cantabria: insights from the clinical programme on early phases of psychosis. Early Interv Psychiatry 2:178–187

    Article  PubMed  Google Scholar 

  34. Petronijevic ND, Radonjic NV, Ivkovic MD, Marinkovic D, Piperski VD, Duricic BM, Paunovic VR (2008) Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32:1921–1926

    Article  PubMed  CAS  Google Scholar 

  35. Reif A, Schneider MF, Kamolz S, Pfuhlmann B (2003) Homocysteinemia in psychiatric disorders: association with dementia and depression, but not schizophrenia in female patients. J Neural Transm 110:1401–1411

    Article  PubMed  CAS  Google Scholar 

  36. Reitan RM, Wolfson D (1985) The Halstead–Reitan neuropsychological test battery: Therapy and clinical interpretation. Neuropsychological Press, Tucson

    Google Scholar 

  37. Rethelyi JM, Czobor P, Polgar P, Mersich B, Balint S, Jekkel E, Magyar K, Meszaros A, Fabian A, Bitter I (2011) General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia. Eur Arch Psychiatry Clin Neurosci [Epub ahead of print]

  38. Rey A (1964) L’examen clinique en psychologie. Presses Universitaires de France, Paris

    Google Scholar 

  39. Russo C, Morabito F, Luise F, Piromalli A, Battaglia L, Vinci A, Trapani Lombardo V, de Marco V, Morabito P, Condino F, Quattrone A, Aguglia U (2008) Hyperhomocysteinemia is associated with cognitive impairment in multiple sclerosis. J Neurol 255:64–69

    Article  PubMed  CAS  Google Scholar 

  40. Segarra R, Ojeda N, Zabala A, Garcia J, Catalan A, Eguiluz JI, Gutierrez M (2011) Similarities in early course among men and women with a first episode of schizophrenia and schizophreniform disorder. Eur Arch Psychiatry Clin Neurosci [Epub ahead of print]

  41. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, Wilson PW, Wolf PA (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 346:476–483

    Article  PubMed  CAS  Google Scholar 

  42. Shallice T (1982) Specific impairments of planning. Philos Trans R Soc Lond B Biol Sci 298:199–209

    Article  PubMed  CAS  Google Scholar 

  43. Spreen OSE (1990) A compendium of neuropsychological tests. Oxford University Press, New York

    Google Scholar 

  44. Stahl Z, Belmaker RH, Friger M, Levine J (2005) Nutritional and life style determinants of plasma homocysteine in schizophrenia patients. Eur Neuropsychopharmacol 15:291–295

    Article  PubMed  CAS  Google Scholar 

  45. Susser E, Brown AS, Klonowski E, Allen RH, Lindenbaum J (1998) Schizophrenia and impaired homocysteine metabolism: a possible association. Biol Psychiatry 44:141–143

    Article  PubMed  CAS  Google Scholar 

  46. Vogel T, Dali-Youcef N, Kaltenbach G, Andres E (2009) Homocysteine, vitamin b12, folate and cognitive functions: a systematic and critical review of the literature. Int J Clin Pract 63:1061–1067

    Article  PubMed  CAS  Google Scholar 

  47. Wechsler D (1997) Wechsler adult intelligence scale, 3rd edn. The Psychological Corporation, San Antonio

Download references

Acknowledgments

Financial support for this study was provided by Instituto de Salud Carlos III (FIS CP07/00008), Fundacio Seny and Fundación Marqués de Valdecilla.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Marqués de Valdecilla University Hospital, IFIMAV, School of Medicine, University of Cantabria, Avda. Valdecilla s/n, 39008, Santander, Spain

    Rosa Ayesa-Arriola, Rocío Pérez-Iglesias, José Manuel Rodríguez-Sánchez, Ignacio Mata, Elsa Gómez-Ruiz, Obdulia Martínez-García, Jose L. Vázquez-Barquero & Benedicto Crespo-Facorro

  2. CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain

    Rosa Ayesa-Arriola, Rocío Pérez-Iglesias, José Manuel Rodríguez-Sánchez, Ignacio Mata, Rafael Tabares-Seisdedos, Jose L. Vázquez-Barquero & Benedicto Crespo-Facorro

  3. Department of Endocrinology, Marqués de Valdecilla University Hospital, University of Cantabria, Santander, Spain

    Maite García-Unzueta

  4. Department of Medicine, University of Valencia, Valencia, Spain

    Rafael Tabares-Seisdedos

Authors
  1. Rosa Ayesa-Arriola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rocío Pérez-Iglesias
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. José Manuel Rodríguez-Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ignacio Mata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elsa Gómez-Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maite García-Unzueta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Obdulia Martínez-García
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rafael Tabares-Seisdedos
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jose L. Vázquez-Barquero
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Benedicto Crespo-Facorro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rosa Ayesa-Arriola.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 20 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ayesa-Arriola, R., Pérez-Iglesias, R., Rodríguez-Sánchez, J.M. et al. Homocysteine and cognition in first-episode psychosis patients. Eur Arch Psychiatry Clin Neurosci 262, 557–564 (2012). https://doi.org/10.1007/s00406-012-0302-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-012-0302-2

Keywords

Search

Navigation